NASA Flight Facility Successfully Launches Nanosatellite

PharmaSat will investigate the effects of antifungal agents on the growth of yeast in microgravity. This research could improve understanding of how microbes may become resistant to the drugs used to treat sick astronauts on long-duration space missions.

"After a spectacular launch as a hitchhiker on the Tacsat-3 mission, we made contact with PharmaSat and confirmed that the spacecraft deployed successfully," said Bruce Yost, PharmaSat mission manager at NASA's Ames Research Center in Moffett Field, Calif. "The PharmaSat mission and science teams are now preparing to complete the experiment on the yeast cultures."

Approximately 20 minutes after launch, PharmaSat separated from the Minotaur 1 rocket and entered low Earth orbit at an altitude of approximately 285 miles. About an hour after launch, NASA spaceflight engineers made contact with PharmaSat. After a spacecraft checkout period, ground controllers will command PharmaSat to initiate its biological experiment, which will last approximately 96 hours.

Now that PharmaSat is activated and has begun transmitting radio signals to ground control stations at SRI International in Menlo Park, Calif., and Santa Clara University in California, it will send mission data to the NASA Mission Management Team at NASA's Ames Research Center. The nanosatellite could transmit data for as long as six months.

The TacSat-3 launch was the third Minotaur vehicle launched from the Mid-Atlantic Regional Spaceport's launch pad 0B on the southern end of Wallops Island. Air Force Space Command's Space and Missile Systems Center's Space Development and Test Wing at Kirtland AFB, N.M., has overall management of the mission.

The Exploration Technology Development Program in NASA's Exploration Systems Mission Directorate at NASA Headquarters in Washington funded the PharmaSat project.

For information about PharmaSat, visit:

http://www.nasa.gov/mission_pages/smallsats/pharmasat.html